13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002026172
Total reported value
$791.3M
$791.3M
119 檔
23.2%
During the Q4 2025 filing period, Diadema Partners LP (CIK: 0002026172) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $791.3M across 119 reported positions.
In Q4 2025, Diadema Partners LP displayed an active expansion posture, initiating 46 new positions and adding to 42 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 8.14% | +3.36% | +124.19% | |
| 2 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 7.68% | -7.37% | EXIT | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.40% | -1.08% | EXIT | |
| 4 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.25% | — | — | |
| 5 | PRAX | Praxis Precision Medicines I | Stock-Other | 5.11% | — | +0.60% | |
| 6 | JNJ | Johnson & Johnson | Stock-Healthcare | 4.15% | -1.53% | — | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 4.08% | — | +42.55% | |
| 8 | CAPR | Capricor Therapeutics Inc | Stock-Other | 3.33% | -2.71% | +123.46% | |
| 9 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 3.17% | — | — | |
| 10 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.08% | -1.76% | EXIT | |
| 11 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.86% | -1.63% | EXIT | |
| 12 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.74% | -3.19% | EXIT | |
| 13 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.30% | -1.64% | EXIT | |
| 14 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.03% | — | -49.27% | |
| 15 | ABVX | Abivax Sa-adr | Stock-Other | 1.76% | +7.67% | +81.75% | |
| 16 | INCY | Incyte CORP | Stock-Healthcare | 1.70% | -1.43% | — | |
| 17 | INSM | Insmed Inc | Stock-Healthcare | 1.58% | — | — | |
| 18 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.50% | +0.84% | -31.25% | |
| 19 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.47% | — | -6.54% | |
| 20 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.45% | — | +6.20% | |
| 21 | QURE | uniQure N.V. | Stock-Other | 1.43% | +1.50% | +15.60% | |
| 22 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.39% | +1.11% | +776.40% | |
| 23 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.19% | -1.58% | EXIT | |
| 24 | ZYME | Zymeworks Inc | Stock-Other | 1.19% | -0.14% | +33.33% | |
| 25 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.15% | -0.64% | +267.56% | |
| 26 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.14% | — | +298.83% | |
| 27 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 1.02% | -0.86% | EXIT | |
| 28 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.84% | -5.20% | — | |
| 29 | MNKD | Mannkind CORP | Stock-Other | 0.83% | -0.07% | -31.76% | |
| 30 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.82% | -0.01% | +12.57% | |
| 31 | COGT | Cogent Biosciences Inc | Stock-Other | 0.81% | +0.30% | -55.73% | |
| 32 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 0.73% | — | +69.92% | |
| 33 | BIOA | Bioage Labs Inc | Stock-Other | 0.67% | +0.89% | — | |
| 34 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.64% | — | -75.56% | |
| 35 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.61% | +0.11% | NEW | |
| 36 | ANNX | Annexon Inc | Stock-Other | 0.57% | -0.19% | — | |
| 37 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.52% | — | +6.23% | |
| 38 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.51% | +0.07% | — | |
| 39 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.51% | -0.12% | -37.34% | |
| 40 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.48% | — | — | |
| 41 | GOSS | Gossamer Bio Inc | Stock-Other | 0.47% | — | +6.34% | |
| 42 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.47% | +0.51% | -57.52% | |
| 43 | ABUS | Arbutus Biopharma CORP | Stock-Other | 0.45% | — | +6.26% | |
| 44 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.42% | +0.03% | -43.48% | |
| 45 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.41% | -0.21% | EXIT | |
| 46 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 0.40% | — | — | |
| 47 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.40% | -0.13% | EXIT | |
| 48 | BHVN | Biohaven Ltd. | Stock-Other | 0.39% | +0.14% | — | |
| 49 | REPL | Replimune Group Inc | Stock-Other | 0.39% | +0.68% | -62.27% | |
| 50 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.37% | +0.58% | -80.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VKTX | Viking Therapeutics Inc | +4.1% | +124.19% | Add |
| 2 | PRAX | Praxis Precision Medicines I | +3.8% | +0.60% | Add |
| 3 | BBIO | Bridgebio Pharma Inc | +3.7% | +211.72% | Add |
| 4 | CAPR | Capricor Therapeutics Inc | +2.8% | +123.46% | Add |
| 5 | 430 | Terns Pharmaceuticals Inc | +1.8% | -25.13% | Trim |
| 6 | RNAGBP | Avidity Biosciences Inc | +1.5% | +42.55% | Add |
| 7 | ABVX | Abivax Sa-adr | +0.9% | +81.75% | Add |
| 8 | CORT | Corcept Therapeutics Inc | +0.8% | +776.40% | Add |
| 9 | APGE | Apogee Therapeutics Inc | +0.8% | +10.15% | Add |
| 10 | OCUL | Ocular Therapeutix Inc | +0.7% | +298.83% | Add |
| 11 | TGTX | Tg Therapeutics Inc | +0.6% | +267.56% | Add |
| 12 | ZYME | Zymeworks Inc | +0.3% | +33.33% | Add |
| 13 | TVTX | Travere Therapeutics Inc | +0.3% | +16666.67% | Add |
| 14 | VTYXUSD | Ventyx Biosciences Inc | +0.3% | +180.88% | Add |
| 15 | OLMA | Olema Pharmaceuticals Inc | +0.2% | +6.19% | Add |
| 16 | SLS | Sellas Life Sciences Group I | +0.1% | +6.22% | Add |
| 17 | XERS | Xeris Biopharma Holdings Inc | +0.1% | +128.18% | Add |
| 18 | MLTX | Moonlake Immunotherapeutics | +0.1% | +80.84% | Add |
| 19 | PTHS | Pelthos Therapeutics Inc | +0.1% | +138.14% | Add |
| 20 | CRMD | Cormedix Inc | 0% | +59.00% | Add |
| 21 | KOD | Kodiak Sciences Inc | 0% | +2.42% | Add |
| 22 | TRVI | Trevi Therapeutics Inc | 0% | +13.23% | Add |
| 23 | AYTU | Aytu Biopharma Inc | 0% | +12.15% | Add |
| 24 | APLT | Applied Therapeutics Inc | — | +6.32% | Add |
| 25 | JBIO | Jade Biosciences Inc | — | — | Unchanged |
| 26 | ANIP | Ani Pharmaceuticals Inc | 0% | +69.92% | Add |
| 27 | PRTCY | Puretech Health PLC - Adr | 0% | +1.61% | Add |
| 28 | FLNA | Filana Therapeutics Inc | 0% | +7.07% | Add |
| 29 | EQ | Equillium Inc | 0% | +15.80% | Add |
| 30 | CRVS | Corvus Pharmaceuticals Inc | 0% | +6.20% | Add |
| 31 | FHTX | Foghorn Therapeutics Inc | 0% | -38.74% | Trim |
| 32 | NEUP | Neuphoria Therapeutics Inc | 0% | +133.08% | Add |
| 33 | ✓ | Proqr Therapeutics N.v. | 0% | +6.24% | Add |
| 34 | TECX | Tectonic Therapeutic Inc | 0% | +0.60% | Add |
| 35 | ATYR | Atyr Pharma Inc | 0% | -86.68% | Trim |
| 36 | GOSS | Gossamer Bio Inc | -0.1% | +6.34% | Add |
| 37 | INDV | Indivior Pharmaceuticals, Inc. | -0.1% | -6.54% | Trim |
| 38 | ALT | Altimmune Inc | -0.1% | +6.22% | Add |
| 39 | PBYI | Puma Biotechnology Inc | -0.2% | -75.13% | Trim |
| 40 | ABUS | Arbutus Biopharma CORP | -0.2% | +6.26% | Add |
| 41 | EDIT | Editas Medicine Inc | -0.2% | +6.23% | Add |
| 42 | PCRX | Pacira Biosciences Inc | -0.2% | -18.50% | Trim |
| 43 | RVMD | Revolution Medicines Inc | -0.2% | -37.34% | Trim |
| 44 | IONS | Ionis Pharmaceuticals Inc | -0.2% | +6.20% | Add |
| 45 | ✓ | Reviva Pharmaceutcls Hldgs I | -0.2% | -80.06% | Trim |
| 46 | AVXL | Anavex Life Sciences CORP | -0.2% | +0.57% | Add |
| 47 | REPL | Replimune Group Inc | -0.3% | -62.27% | Trim |
| 48 | COGT | Cogent Biosciences Inc | -0.3% | -55.73% | Trim |
| 49 | ARDX | Ardelyx Inc | -0.3% | -36.95% | Trim |
| 50 | RXRX | Recursion Pharmaceuticals-a | -0.4% | +6.23% | Add |
According to official SEC Form 13F filings, Diadema Partners LP reported a total U.S. public equity portfolio value of $791.3M across 119 disclosed positions in Q4 2025.
During Q4 2025, Diadema Partners LP's top holdings by market value included VKTX (8.1%)、VRTX (7.7%)、BBIO (5.4%). The largest single position, VKTX, represented 8.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VKTX, VRTX, BBIO) accounted for 23.2% of total reported equity market value during Q4 2025.
Top New Position Initiated
VRTX
市值: $44.6M
Top Position Liquidated / Trimmed
BMY
前期市值: $14.0M
In Q4 2025, Diadema Partners LP made 150 total portfolio adjustments, initiating 46 new buys, adding to 42 positions, trimming 29 holdings, and fully liquidating 33 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.